Latest News and Press Releases

NESS-ZIONA, ISRAEL--(Marketwired - January 30, 2018) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer immunotherapy company, is pleased to announce the closing of an oversubscribed...

NESS-ZIONA, ISRAEL--(Marketwired - December 05, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli immuno-oncology biotechnology company, is pleased to announce the addition of two...

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - July 24, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, is pleased...

TORONTO, ON, and NESS ZIONA, ISRAEL--(Marketwired - May 23, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), a biopharmaceutical company focused on developing immunotherapies based on signal peptides from...

NESS ZIONA, ISRAEL and TORONTO, ON--(Marketwired - March 03, 2017) - Vaxil Bio Ltd. ("Vaxil", or the "Company") (TSX VENTURE: VXL) is pleased to announce that the Company's abstract illustrating...

NESS-ZIONA, ISRAEL and TORONTO, ON--(Marketwired - February 09, 2017) - Vaxil Bio Ltd. ("Vaxil", or the "Company") (TSX VENTURE: VXL) today announces its participation in the Annual BIO CEO and...

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - January 19, 2017) - VAXIL BIO (TSX VENTURE: VXL), a biotech specializing in immunotherapy, announces today that it has received an important Notice of...

TORONTO, ON and NESS-ZIONA, ISRAEL--(Marketwired - January 04, 2017) - Vaxil Bio Ltd. (TSX VENTURE: VXL) -- Following Vaxil's recent announcement that it had received encouraging preliminary results...

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - November 29, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL) is pleased to report preliminary pre-clinical results demonstrating anti-cancer activity of...

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - October 20, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), is pleased to announce a collaboration with Hadassah Medical Center, one of Israel's leading...